Trial · NCT00862563
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Zonisamide | Week 10 | 3.8 | Standard Error 0.9 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Sugar Pill | Week 10 | 6.3 | Standard Error 0.9 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Topiramate | Week 10 | 3.2 | Standard Error 0.8 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Levetiracetam | Week 10 | 4.6 | Standard Error 0.8 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Zonisamide | Week 11 | 3.4 | Standard Error 0.6 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Sugar Pill | Week 11 | 6.8 | Standard Error 1.2 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Topiramate | Week 11 | 2.7 | Standard Error 0.7 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Levetiracetam | Week 11 | 4.3 | Standard Error 0.7 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Zonisamide | Week 12 | 2.5 | Standard Error 0.7 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Sugar Pill | Week 12 | 6.0 | Standard Error 0.9 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Topiramate | Week 12 | 2.5 | Standard Error 0.7 | Standard Drinks per day |
The Primary Efficacy Measure is the Mean Number of Drinks Consumed Per Day Over the Period From Treatment Weeks 10 Through 12 When All Study Medications Should be at Their Maximum Steady Levels Based on Their Known Pharmacokinetic Properties. | Levetiracetam | Week 12 | 4.3 | Standard Error 0.7 | Standard Drinks per day |
| AB-Neurotoxicity Scale. | Zonisamide | 7.1 | Standard Error 2.2 | Scale Scores | |
| AB-Neurotoxicity Scale. | Levetiracetam | 11.3 | Standard Error 2.7 | Scale Scores | |
| AB-Neurotoxicity Scale. | Topiramate | 15.4 | Standard Error 3.3 | Scale Scores | |
| AB-Neurotoxicity Scale. | Sugar Pill | 5.8 | Standard Error 1.6 | Scale Scores | |
| Mean Percent Days Heavy Drinking | Zonisamide | Week 10 | 38.4 | Standard Error 10.7 | Percentage of Days/Week |
| Mean Percent Days Heavy Drinking | Sugar Pill | Week 10 | 65.7 | Standard Error 6.5 | Percentage of Days/Week |
| Mean Percent Days Heavy Drinking | Topiramate | Week 10 | 32.1 | Standard Error 8.5 | Percentage of Days/Week |
| Mean Percent Days Heavy Drinking | Levetiracetam | Week 10 | 49.6 | Standard Error 9.4 | Percentage of Days/Week |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00862563/results